CompuMed, Inc.
CompuMed, Inc. (CMPD) Financial Performance & Income Statement Overview
Explore the financials of CompuMed, Inc. (CMPD), including yearly and quarterly data on income, cash flow, and balance sheets.
CompuMed, Inc. (CMPD) Income Statement & Financial Overview
Access detailed annual and quarterly income data for CompuMed, Inc. CMPD financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $1.67M | $1.62M | $1.64M | $1.55M |
| Cost of Revenue | $885869.00 | $852731.00 | $844286.00 | $806884.00 |
| Gross Profit | $780167.00 | $765806.00 | $799875.00 | $743650.00 |
| Gross Profit Ratio | $0.47 | $0.47 | $0.49 | $0.48 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $752315.00 | $734250.00 | $694802.00 | $670668.00 |
| Operating Expenses | $752315.00 | $734250.00 | $694802.00 | $670668.00 |
| Total Costs & Expenses | -$1.64M | -$1.59M | $1.54M | $1.48M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $11589.00 | $12141.00 | $7322.00 | $9252.00 |
| Depreciation & Amortization | $174033.00 | $176850.00 | $173372.00 | $181491.00 |
| EBITDA | $208275.00 | $218856.00 | $285185.00 | $259993.00 |
| EBITDA Ratio | $0.13 | $0.14 | $0.17 | $0.17 |
| Operating Income | $27852.00 | $31556.00 | $105070.00 | $72980.00 |
| Operating Income Ratio | $0.02 | $0.02 | $0.06 | $0.05 |
| Other Income/Expenses (Net) | -$5196.00 | -$1688.00 | -$580.00 | -$3735.00 |
| Income Before Tax | $22656.00 | $29868.00 | $104490.00 | $69247.00 |
| Income Before Tax Ratio | $0.01 | $0.02 | $0.06 | $0.04 |
| Income Tax Expense | $0.00 | $0.00 | $3569.00 | $200.00 |
| Net Income | $22656.00 | $29868.00 | $100921.00 | $69047.00 |
| Net Income Ratio | $0.01 | $0.02 | $0.06 | $0.04 |
| EPS | $0.02 | $0.02 | $0.08 | $0.05 |
| Diluted EPS | $0.02 | $0.02 | $0.08 | $0.05 |
| Weighted Avg Shares Outstanding | $1.32M | $1.32M | $1.32M | $1.32M |
| Weighted Avg Shares Outstanding (Diluted) | $1.32M | $1.32M | $1.32M | $1.32M |
The company's financials show resilient growth, with revenue advancing from $1.55M in Q2 2024 to $1.67M in Q1 2025. Gross profit remained healthy with margins at 47% in Q1 2025 compared to 48% in Q2 2024. Operating income hit $27852.00 last quarter, sustaining a consistent 2% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $208275.00. Net income dropped to $22656.00, while earnings per share reached $0.02. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan